SCHEMBL3620246

SCHEMBL3620246

CCCCn1c(=O)n(CCc2ccccc2)c(=O)c2[nH]c(Cl)nc21

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 1/20 0.61
SIRT3 Q9NTG7 1/20 0.61
SIRT5 Q9NXA8 1/20 0.61
ADORA2A P29274 5/20 0.58
ADORA2B P29275 5/20 0.58
ADORA1 P30542 4/20 0.58
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
KMT2A Q03164 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ADORA3 P0DMS8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3106241 0.95 ADORA2B (0.58) SIRT1SIRT3SIRT5ADORA2AADORA2B
SCHEMBL3115718 0.92 ADORA2A (0.55) SIRT1SIRT3SIRT5ADORA2AADORA2B
SCHEMBL3611280 0.91 ADORA2A (0.60) ADORA2AADORA2BADORA1KDM4EMEN1
SCHEMBL3121394 0.87 ADORA2A (0.49) SIRT1SIRT3SIRT5ADORA2AADORA2B
SCHEMBL7031457 0.87 SIRT1 (0.55) SIRT1SIRT3SIRT5ADORA2AADORA2B
SCHEMBL3119031 0.86 ADORA2B (0.54) SIRT1SIRT3SIRT5ADORA2AADORA2B
SCHEMBL843582 0.86 ADORA2B (0.54) SIRT1SIRT3SIRT5ADORA2AADORA2B
SCHEMBL3111070 0.85 KDM4E (0.51) ADORA2AADORA2BADORA1KDM4EALDH1A1
SCHEMBL3119443 0.85 SIRT1 (0.54) SIRT1SIRT3SIRT5ADORA2AADORA2B
SCHEMBL836300 0.85 ADORA2B (0.55) ADORA2AADORA2BADORA1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099690-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-04-22 US disclosed
US-20100099690-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-04-22 US disclosed
US-20100099690-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-04-22 US disclosed
EP-1912993-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SmithKline Beecham Corporation (US) 2008-04-23 EP disclosed
WO-2007017265-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099690-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GPR84, GPR88, HCAR1 SIRT1 1483/4885SIRT3 3159/4885SIRT5 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.